Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial

IMPORTANCE: Angiosarcoma is a rare sarcoma subtype with a poor outcome. Carotuximab plus pazopanib produced a median progression-free survival (PFS) of 7.8 months in pazopanib-naive patients with chemotherapy-refractory angiosarcoma in a phase 1/2 trial. OBJECTIVE: To determine whether carotuximab p...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Robin L., Ravi, Vinod, Brohl, Andrew S., Chawla, Sant, Ganjoo, Kristen N., Italiano, Antoine, Attia, Steven, Burgess, Melissa A., Thornton, Katherine, Cranmer, Lee D., Cheang, Maggie Chon U., Liu, Lingyun, Robertson, Liz, Adams, Bonne, Theuer, Charles, Maki, Robert G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972152/
https://www.ncbi.nlm.nih.gov/pubmed/35357396
http://dx.doi.org/10.1001/jamaoncol.2021.3547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972152/
https://www.ncbi.nlm.nih.gov/pubmed/35357396
http://dx.doi.org/10.1001/jamaoncol.2021.3547

Ejemplares similares